Shopping Cart 0
Cart Subtotal
USD 0

XTL Biopharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

XTL Biopharmaceuticals Ltd (XTL) is a drug development company that focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company's pipeline products include hCDR1 peptide and recombinant human erythropoietin. Its hCDR1 peptide is used for the treatment of systemic lupus erythematosus. XTL's recombinant human erythropoietin is a compound developed for the prolongation of multiple myeloma advanced-stage patients' survival and is used in clinical practice for the treatment of various anemias including anemia of kidney disease and cancer-related anemia. The company's pipeline is generated by identifying, validating and in-licensing therapeutic candidates. XTL is headquartered in Ra'anana, Israel.

XTL Biopharmaceuticals Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

XTL Biopharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

XTL Biopharma Amends Licensing Agreement with Yeda Research for hCDR1 11

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 13

Equity Offering 14

XTL Biopharma Raises USD2.8 Million in Private Placement of ADS and Warrants 14

XTL Biopharma Prices Private Placement of American Depositary Shares to Raise USD4 Million 15

XTL Biopharma Completes Private Placement Of Shares For USD 1.1 Million Upon Exercise Of Warrants 16

XTL Biopharma Completes Private Placement Of Securities For USD 2.4 Million 17

Acquisition 18

Zmiha Investment House Acquires 45% Stake In Proteologics For USD 3.4 Million 18

XTL Biopharma Acquires 31% Stake In Proteologics From Teva For USD 2 Million 19

XTL Biopharma Acquires 50.79% Stake in InterCure for USD2.7 Million 20

XTL Biopharma To Acquire Kitov Pharma, Drug Development Company 21

XTL Biopharmaceuticals Ltd-Key Competitors 23

XTL Biopharmaceuticals Ltd-Key Employees 24

XTL Biopharmaceuticals Ltd-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

May 29, 2018: XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update 26

Nov 27, 2017: XTL Biopharma Reports Third Quarter 2017 Financial Results 27

Sep 26, 2017: XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update 28

Mar 30, 2017: XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update 30

Corporate Communications 31

Apr 27, 2017: XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors 31

Appendix 32

Methodology 32

About GlobalData 32

Contact Us 32

Disclaimer 32


List Of Figure

List of Figures

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

XTL Biopharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts 2

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

XTL Biopharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

XTL Biopharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

XTL Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

XTL Biopharma Amends Licensing Agreement with Yeda Research for hCDR1 11

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 13

XTL Biopharma Raises USD2.8 Million in Private Placement of ADS and Warrants 14

XTL Biopharma Prices Private Placement of American Depositary Shares to Raise USD4 Million 15

XTL Biopharma Completes Private Placement Of Shares For USD 1.1 Million Upon Exercise Of Warrants 16

XTL Biopharma Completes Private Placement Of Securities For USD 2.4 Million 17

Zmiha Investment House Acquires 45% Stake In Proteologics For USD 3.4 Million 18

XTL Biopharma Acquires 31% Stake In Proteologics From Teva For USD 2 Million 19

XTL Biopharma Acquires 50.79% Stake in InterCure for USD2.7 Million 20

XTL Biopharma To Acquire Kitov Pharma, Drug Development Company 21

XTL Biopharmaceuticals Ltd, Key Competitors 23

XTL Biopharmaceuticals Ltd, Key Employees 24

XTL Biopharmaceuticals Ltd, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

XTL Biopharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.